Agios to Present Updated Clinical Data from PKR Activator AG-348 at EHA
The accepted abstracts are listed below and available online on the EHA conference website: http://learningcenter.ehaweb.org/eha/#!*listing=3*browseby=2*sortby=1*media=3*ce_id=1181*label=15531
Oral presentation by Agios:
Title: Effects of AG-348, a pyruvate kinase activator, in patients with Pyruvate Kinase Deficiency: updated results from the DRIVE-PK study
Date & Time:
Session Title: Sickle cell disease, enzymes
Abstract Code: S451
Location:
Presenter:
Updated data from the DRIVE PK study will be presented at the time of the meeting.
Poster presentation by Agios collaborator:
Title: Ex-vivo treatment of red blood cells from 15 Pyruvate Kinase (PK)-deficient patients with AG-348, an allosteric activator of PK-R, increases enzymatic activity, protein stability and ATP levels
Date & Time:
Session Title: Enzymes and sickle cell disease
Abstract Code: P614
Location: Poster area (Hall 7)
Author:
Encore presentations by Agios and
Title: Enasidenib in mutant-IDH2 relapsed or refractory acute myeloid leukemia (R/R AML): Results of a phase 1 dose-escalation and expansion study
Date & Time:
Oral Abstract Session: Targeted treatment of AML
Abstract Code: S471
Location: Hall D
Presenter:
Title: Differentiation syndrome associated with enasidenib, a selective inhibitor of mutant isocitrate dehydrogenase 2 (mIDH2)
Poster Session Date & Time:
Session Title: Acute myeloid leukemia - Clinical 3
Abstract Code: P215
Location: Poster area (Hall 7)
Author: Amir Tahmasb Fathi, M.D.,
About Agios
Agios is focused on discovering and developing novel investigational medicines to treat cancer and rare genetic diseases through scientific leadership in the field of cellular metabolism. In addition to an active research and discovery pipeline across both therapeutic areas, Agios has multiple first-in-class investigational medicines in clinical and/or preclinical development. All Agios programs focus on genetically identified patient populations, leveraging our knowledge of metabolism, biology and genomics. For more information, please visit the company's website at www.agios.com.
About Agios/Celgene Collaboration
IDHIFA® (enasidenib) and AG-881 are part of Agios' global strategic collaboration with
Cautionary Note Regarding Forward-Looking Statements
This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Such forward-looking statements include those regarding Agios’ plans, strategies and expectations for its and its collaborators’ preclinical, clinical and commercial advancement of its drug development programs including AG-348 and IDHIFA® (enasidenib); the potential benefits of Agios' product candidates; its plans regarding future data presentations; and the potential benefit of its strategic plans and focus. The words “intend,” “will,” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Such statements are subject to numerous important factors, risks and uncertainties that may cause actual events or results to differ materially from Agios' current expectations and beliefs. For example, there can be no guarantee that any product candidate Agios or its collaborator,
Contacts Investors:Kendra Adams , 617-844-6407 Senior Director, Investor & Public Relations Kendra.Adams@agios.comRenee Leck , 617-649-8299 Senior Manager, Investor & Public Relations Renee.Leck@agios.com Media:Holly Manning , 617-844-6630 Associate Director, Corporate Communications Holly.Manning@agios.com